Verisys

FEBRUARY 7, 2024

The more you know about the people in your organization, the safer you are from risks that could damage your company, your reputation, or your compliance.The regulations in the pharmaceutical industry are understandably strict, and to ensure your organization is compliant, every member of your team must be thoroughly vetted.

Compliance 52

Compliance Licensing Compliance Framework Fraud 52

Verisys

JULY 13, 2023

The onus of ensuring these CROs have proper controls in place often falls on the shoulders of the pharmaceutical company and can be challenging to monitor. Medication Samples Supplying medication samples to prescriber’s offices is common in the pharmaceutical industry, especially with launch brands.

Compliance 52

Compliance Due Diligence Pharmaceutical Industry Fraud 52

Hall Render

APRIL 21, 2023

Nevada, currently the wild west of birthing, is considering licensing midwifery NEW HAMPSHIRE Dartmouth Health opens new 5-story patient pavilion Report: Anthem has yet to process nearly $300 million in N.H. health care fraud scheme SA cancer research company entering Dallas market as it eyes more U.S.,

US Department of Health and Human Services 40

US Department of Health and Human Services COVID-19 Nurses Nursing Homes 40

Hall Render

FEBRUARY 18, 2022

License wait times reach crisis levels for healthcare workers. Florida physician convicted of $110M fraud. Bill on prescription drug pricing inspires support from Maine residents, opposition from pharmaceutical industry. billing fraud. 3 Texas medical labs charged in $300M fraud scheme.

COVID-19 40

COVID-19 Nursing Homes Nurses COVID-19 Vaccine 40

Drug & Device Law

MARCH 7, 2022

Here, Plaintiffs fail to supply factual support showing Defendant acted with “oppression, fraud, or malice,” relying instead upon conclusory allegations. Punitive damages are available when the evidence shows that the defendant acted with fraud, malice, or gross negligence. . . . [T]he at *8 (agreeing with Bouncing Angels, Inc.

Fraud 59

Fraud FDA Licensing Pharmaceutical Industry 59

Drug & Device Law

NOVEMBER 4, 2023

Plaintiffs’ counsel seem to be increasingly setting their sights on the OTC segment of the pharmaceutical industry, where the Learned Intermediary Doctrine does not serve as a barrier, where vast use of OTC products expands the range of potential plaintiffs, and where litigation can target well-known prescription drug parent companies.

FDA 59

FDA Pharmaceutical Industry Licensing Fraud 59